medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-3-58-65medsovet-60Research ArticleКоморбидные состоянияComorbid conditionsНовые возможности лечения пациента с сахарным диабетом и сердечной недостаточностью. Обобщенный российский опытNew options in the treatment of patients with diabetes and heart failure. Generalized Russian experienceАметовА. С.AmetovА. S.noemail@neicon.ruДоскинаЕ. В.DoskinaE. V.noemail@neicon.ruРоссийская медицинская академия последипломного образованияРоссияRussian Medical Academy of Postgraduate EducationRussian Federation201630122016035865Copyright © Аметов А.С., Доскина Е.В., 20162016Аметов А.С., Доскина Е.В.Ametov А.S., Doskina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/60

В статье рассматривается обобщенный российский опыт лечения пациентов с сахарным диабетом и сердечной недостаточностью. Показана роль препаратов, влияющих на различные звенья патогенеза сахарного диабета в лечении пациентов с сопутствующими сердечно-сосудистыми заболеваниями. Указана роль таурина как оптимального дополнения к сахароснижающей терапии у данной группы пациентов.

The article tells about generalized Russian experience in the treatment of patients with diabetes and heart failure. The role of medicines affecting various links in the pathogenesis of diabetes mellitus in patients with concomitant cardiovascular diseases is deminstrated. The role of taurine as the optimum addition to glucose-lowering therapy in this group of patients is emphasized.

сахарный диабетсердечная недостаточностьлечениетауринdiabetesheart failuretreatmenttaurineReferenceshttp://www.diabetesatlas.org/http://www.diabetesatlas.org/Clark CM, Perry RC. Type 2 diabetes and macro-vascular disease: epidemiology and etiology. Am. Heart J., 1999, 138(5), Pt. 1: S330-S333.Clark CM, Perry RC. Type 2 diabetes and macro-vascular disease: epidemiology and etiology. Am. Heart J., 1999, 138(5), Pt. 1: S330-S333.Fchtenbusch M, Standl E, Otter W, Hummel M. Diabetes mellitus and heart failure. MMW. Fortschr. Med., 2007, 149(37): 41-44.Fchtenbusch M, Standl E, Otter W, Hummel M. Diabetes mellitus and heart failure. MMW. Fortschr. Med., 2007, 149(37): 41-44.The CONSENSUS trial study group. Effect of enal-april on mortality in severe congestive heart failure. N Engl J Med., 1987, 316: 1429-1435.The CONSENSUS trial study group. Effect of enal-april on mortality in severe congestive heart failure. N Engl J Med., 1987, 316: 1429-1435.The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med., 1991, 325: 293302.The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med., 1991, 325: 293302.Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med., 1991, 325: 303-310.Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med., 1991, 325: 303-310.Packer M, Poole-Wilson PA, Armstrong PM et al. on behalf of the ATLAS Study Group. Comparative effects of low doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Submitted, 1998.Packer M, Poole-Wilson PA, Armstrong PM et al. on behalf of the ATLAS Study Group. Comparative effects of low doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Submitted, 1998.From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am. J. Med., 2006, 119(7): 591-599.From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am. J. Med., 2006, 119(7): 591-599.Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J. Card. Fail., 2009, 15(4): 305-309.Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J. Card. Fail., 2009, 15(4): 305-309.Masoudi F.A., Inzucchi S.E. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am. J. Cardiol., 2007, 99(4A): 113B-132B.Masoudi F.A., Inzucchi S.E. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am. J. Cardiol., 2007, 99(4A): 113B-132B.Vaur L, Gueret P, Lievre M et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care, 2003, 26(3): 855-860.Vaur L, Gueret P, Lievre M et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care, 2003, 26(3): 855-860.Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care, 2004, 27(3): 699-703.Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care, 2004, 27(3): 699-703.Yamory et al. Taurine and Cardiac study, 2006.Yamory et al. Taurine and Cardiac study, 2006.Мановицкая А.В. Метаболическая терапия у пациентов с метаболическим синдромом. Поликлиника, 2012, 2/1: 25-28.Мановицкая А.В. Метаболическая терапия у пациентов с метаболическим синдромом. Поликлиника, 2012, 2/1: 25-28.Manovitskaya A.V. Metabolic therapy in patients with metabolic syndrome. Poliklinika, 2012, 2/1: 25-28.Manovitskaya A.V. Metabolic therapy in patients with metabolic syndrome. Poliklinika, 2012, 2/1: 25-28.

The authors declare that there are no conflicts of interest present.